Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;8(4):297-302.
doi: 10.14740/jocmr2496w. Epub 2016 Feb 27.

The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma

Kang Liu  1 , Xu-Li Min  2 , Juan Peng  2 , Ke Yang  2 , Lin Yang  2 , Xiao-Ming Zhang  2
Affiliations
Review

The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma

Kang Liu et al. J Clin Med Res. 2016 Apr.

Abstract

As a common malignant tumor, hepatocellular carcinoma (HCC) has a high prevalence and is a serious threat to human health. The surgical resection rate of HCC is low, and the prognosis is poor. Although transarterial chemoembolization (TACE) is the main treatment for HCC patients who are not candidates for surgical resection, it is not considered a curative procedure. For HCC, poor TACE efficacy or TACE failure may be related to tumor angiogenesis of the residual disease. Among the many regulatory factors in tumor angiogenesis, hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) play vital roles in this process. In this paper, we conducted a review of the dynamic change and relevance of HIF-1α and VEGF levels after TACE of HCC patients.

Keywords: Hepatocellular carcinoma; Hypoxia-inducible factor-1α; Transarterial chemoembolization; Vascular endothelial growth factor.

PubMed Disclaimer

References

    1. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008;7(3):237–257. - PubMed
    1. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181–200. doi: 10.1055/s-2005-871198. - DOI - PubMed
    1. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer. 2009;45(6):931–991. doi: 10.1016/j.ejca.2008.11.018. - DOI - PubMed
    1. Omyla-Staszewska J, Deptala A. Effective therapeutic management of hepatocellular carcinoma - on the basis of a clinical case. Contemp Oncol (Pozn) 2012;16(1):60–63. - PMC - PubMed
    1. Wang YX, De Baere T, Idee JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res. 2015;27(2):96–121. - PMC - PubMed